F-star
Merck KGaA takes second option from cancer immunotherapy pact with F-Star
Richard Staines
cancer, F-star, immunotherapy, Merck KGaA, R&D
0 Comment
Merck KGaA to develop immunotherapies with F-star
Richard Staines
Bristol-Myers Squibb, cancer, F-star, immunotherapy, Merck KGaA, UK biotech
0 Comment
German Merck has option to licence LAG3-PDL1 drug.
F-star and Denali sign potential $1bn antibody deal
Richard Staines
Biotech, Bristol-Myers Squibb, Denali, F-star, R&D
0 Comment
Deal focuses on CNS bispecific antibodies.
Articles/ Clinical/ UK & Europe/ Views and analysis
Will the UK ever produce a world-class biotech company?
Andrew McConaghie
Biotech, Cambridge, F-star, Kymab, Mission Therapeutics, UK biotech
0 Comment
Kymab, F-star and Mission Therapeutics among crop of new UK biotechs.